Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: Report of two cases

Acta Oncologica

Volumn 51, Issue 1, 2012, Pages 136-138

  Melichar, Bohuslav ^a,b   Laco, Jan ^b   Fridrichov, Petra ^b   Imkovia, Martin ^b   Papajk, Tom ^a   Foretov, Lenka ^c  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TAMOXIFEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANEMIA; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; CYSTADENOCARCINOMA; CYTOLOGY; DISTANT METASTASIS; DIZZINESS; DRUG TOLERABILITY; DYSPNEA; EPITHELIAL OVARY CANCER; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; GENE MUTATION; GENERAL CONDITION; GENETIC ANALYSIS; HISTOLOGY; HUMAN; LETTER; LEUKOPENIA; LYMPHADENECTOMY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NECROTIZING COLITIS; OMENTECTOMY; OVARY CANCER; PANCYTOPENIA; PARTIAL MASTECTOMY; PELVIS; PERITONEUM METASTASIS; PLEURA EFFUSION; PLEURA METASTASIS; PNEUMONIA; PRIORITY JOURNAL; SYSTEMIC THERAPY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; WEAKNESS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYSTADENOCARCINOMA, SEROUS; FATAL OUTCOME; FEMALE; GENES, BRCA1; HETEROZYGOTE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOPLASMS, SECOND PRIMARY; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM;

EID: 83455246792     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.594810     Document Type: Letter

References (10)

1. McGuire WP., Hoskins WJ., Brady MF., Kucera PR., Partridge EE., Look KY., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage Iv ovarian cancer. N Engl J Med 1996;334:1-6. (Pubitemid 26012496)
2. Dizon DS., Dupont J., Anderson S., Sabbatini P., Hummer A., Aghajanian C., et al. Treatment of recurrent ovarian cancer: A retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. Gyn Oncol 2003;91:584-90. (Pubitemid 38388155)
3. Markman M., Liu PY., Wilczynski S., Monk B., Copeland LJ., Alvarez RD., et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460-5. (Pubitemid 46606325)
4. Travis LB., Holowaty EJ., Bergfeldt K., Lynch CF., Kohler BA., Wiklund T., et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999;340: 351-7. (Pubitemid 29090800)
5. Cole M., Strair R. Acute myelogenous leukemia and myelo-dysplasia secondary to breast cancer treatment: Case studies and literature review. Am J Med Sci 2010;339:36-40.
6. Kennedy RD., Quinn JE., Mullan PB., Johnston PG., Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004;96:1659-68. (Pubitemid 39585635)
7. Chetrit A., Hirsch-Yechezkel G., Ben-David Y., Lubin F., Friedman E., Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The national Israeli study of ovarian cancer. J Clin Oncol 2008;26:20-5.
8. Risch HA., McLaughlin JR., Cole DEC., Rosen B., Bradley L., Kwan E., et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68: 700-10. (Pubitemid 32203724)
9. vardiman JW., Thiele J., Arber DA., Brunning RD., Borowitz MJ., Porwit A., et al. The 2008 revision of the world organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114: 937-51.
10. Friedenson B. The BRCAI/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC Cancer 2007;7:1-11.